NanoString Technologies

NanoString Technologies, Inc. engages in the development and commercialization of instruments and services for profiling of genes and proteins from tissue sample. It offers the GeoMx Digital Spatial Profiler, nCounter Analysis System product platforms, GeoMx Assays, nCounter Panels & Assays and CosMx Spatial Molecular. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June, 2003 and is headquartered in Seattle, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

NanoString Technologies reports robust Q4 revenue and optimistic 2023 outlook

NanoString Technologies showcased strong Q4 2022 performance with revenue exceeding guidance and a positive outlook for 2023.
While facing challenges such as expected EBITDA losses and nCounter revenue decline, NanoString is leveraging opportunities in spatial biology and customer synergies.
The company's strengths lie in market-leading technology, positive customer feedback on CosMx instruments, and a cash-generating nCounter business.
Overall, NanoString's strategic focus on spatial biology and operational improvements position it for continued growth and innovation.

NanoString Technologies surpasses Q1 revenue targets, CosMx shines

NanoString Technologies had a strong Q1 2023, exceeding revenue guidance and raising full-year expectations.
Positive customer feedback and competitive positioning of CosMx in the spatial imager category are key strengths.
Challenges include EBITDA loss, capacity constraints, and shifts in product demand.
Opportunities lie in achieving cash flow breakeven, product growth, and market dominance with CosMx.

NanoString Technologies reports record Q2 revenue and strategic growth plans

NanoString Technologies delivered strong Q2 results, exceeding revenue guidance and showcasing growth in spatial biology.
The company's strategic objectives for 2023 focus on market expansion and product innovation, supported by a commitment to operational efficiency.
While facing challenges such as ongoing litigation and financial discussions, NanoString remains optimistic about its growth prospects and balance sheet strengthening.

NanoString Technologies achieves record revenue, eyes growth opportunities in 2024

NanoString Technologies reported strong revenue growth and cost reduction in Q3 2023.
Focus on spatial biology market penetration and new product offerings to drive future growth.
Legal challenges in Europe and backlog delays pose challenges to be addressed.
Improved gross margins and lower expenses expected to enhance profitability by 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

SEATTLE--(BUSINESS WIRE)--NanoString announces highlights of 2021 Advances in Genome Biology and Technology conference.

NanoString Launches Technology Access Program for the Spatial Molecular Imager (SMI) Platform and Showcases Spatially Resolved Transcriptomic Research at 2021 Advances in Genome Biology and Technology (AGBT) Conference

NanoString Technologies (NASDAQ:NSTG) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for NanoString Technologies's Q4 earnings.

A Preview Of NanoString Technologies's Earnings

SEATTLE--(BUSINESS WIRE)--NanoString to present at the 41st annual Cowen healthcare conference.

NanoString to Webcast Presentation from the 41st Annual Cowen Healthcare Conference

NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: NanoString Technologies (NSTG) Q4 Earnings Expected to Decline

SEATTLE--(BUSINESS WIRE)--NanoString announces launch of GeoMx DSP Whole Transcriptome Atlas.

NanoString Announces the Launch of the Whole Transcriptome Atlas with Data to be Presented at the Third Annual Spatial Genomics Summit on February 23, 2021

SEATTLE--(BUSINESS WIRE)--NanoString to present at 10th Annual SVB Leerink conference.

NanoString to Webcast Presentation from the 10th Annual SVB Leerink Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)--NanoString to release Q4 and FY20 operating results on March 1st, 2021.

NanoString to Release Fourth Quarter and Fiscal Year 2020 Operating Results and Host Conference Call on Monday, March 1, 2021

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the publication of a study in the journal Nature Medicine that used NanoString's GeoMx® Digital Spatial Profiler (DSP) and the new Whole Transcriptome Atlas (WTA) to profile sarcoma tissue. The research was led by a team from the Broad Institute in Cambridge, Massachusetts. The paper, entitled “Opposing immune and genetic mecha

Nature Medicine Publishes First Study Utilizing NanoString's GeoMx Digital Spatial Profiler Whole Transcriptome Atlas

SEATTLE--(BUSINESS WIRE)--NanoString provides preliminary financial and operational highlights for Q4'20.

NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2020

SEATTLE--(BUSINESS WIRE)--NanoString to webcast presentation from the JP Morgan Healthcare conference.

NanoString to Present at the 39th Annual J.P. Morgan Healthcare Conference

SEATTLE--(BUSINESS WIRE)--NanoString's GeoMx DSP Identifies Diverse Immune Responses in COVID-19 Patients.

NanoString's GeoMx Digital Spatial Profiler Identifies Diverse Immune Responses Within COVID-19 Patients in Study Published in Nature Communications

SEATTLE--(BUSINESS WIRE)--NanoString announces development of spatial molecular imaging platform.

NanoString Unveils Spatial Molecular Imaging Platform, Complementing GeoMx DSP to Provide Compelling Product Roadmap for Spatial Biology

SEATTLE--(BUSINESS WIRE)--NanoString announces virtual Investor and Analyst Day.

NanoString to Host Virtual Investor and Analyst Day on December 1st, 2020

SEATTLE--(BUSINESS WIRE)--NanoString and OHSU Announce Collaboration to Develop GeoMx Assays for Breast Cancer

NanoString and Oregon Health & Science University Announce Collaboration to Develop GeoMx-Based Spatial Profiling Assays for Breast Cancer

SEATTLE--(BUSINESS WIRE)--NanoString to present at the 2020 Stifel Healthcare Conference.

NanoString to Present at the Stifel 2020 Virtual Healthcare Conference

SEATTLE--(BUSINESS WIRE)--NanoString announces research highlights from SITC 2020.

NanoString Highlights Growing Body of Spatial Biology Research Presented at the 35th Annual Meeting of the Society of Immunotherapy of Cancer Conference (SITC)

NanoString Technologies, Inc. (NSTG) CEO Bradley Gray on Q3 2020 Results - Earnings Call Transcript

NanoString (NSTG) delivered earnings and revenue surprises of 8.20% and 5.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

NanoString Technologies (NSTG) Reports Q3 Loss, Tops Revenue Estimates

Shares of NanoString Technologies (NASDAQ:NSTG) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 1.56% over the past year to ($0.65), which missed the estimate of ($0.60).

NanoString Technologies: Q3 Earnings Insights

SEATTLE--(BUSINESS WIRE)--NanoString reports Q3 operating results.

NanoString Technologies Releases Operating Results for Third Quarter of 2020

SEATTLE--(BUSINESS WIRE)--NanoString announces commercial launch of spatially resolved protein analysis using next generation sequencing.

NanoString Launches GeoMx DSP Protein Assays for Next Generation Sequencing

SEATTLE--(BUSINESS WIRE)--NanoString to present at virtual Credit Suisse Healthcare conference.

NanoString to Present at the 29th Annual Credit Suisse Healthcare Conference

Will NanoString Technologies (NSTG) Report Negative Earnings Next Week? What You Should Know

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $40.00 per share pursuant to its existing shelf registration statement, for gross proceeds of $230.0 million. The number of shares issued at closing included the exercise in full of the underw

NanoString Technologies Announces Closing of Public Offering of $230.0 Million of Common Stock Including Exercise in Full of Option to Purchase Additional Shares

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis tools, today announced a key milestone in their partnership to develop new analysis tools to accelerate research on NanoString’s nCounter® Analysis System. After successful completion of an Early Access Program announced in May, the parties are expanding access to new analys

News for NanoString Technologies Stock (NSTG)